Open Payments

Childrens Mercy Hospital

Type
Teaching hospital
Where
Kanas City, MO
Medicare CCN
263302
Received
$3,026,113 in 949 records, 2023 ($503,418 general, $2,522,694 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2023General payment29$503,418
2023Research payment920$2,522,694

By company

CompanyRecordsAmountYears
VERTEX PHARMACEUTICALS INCORPORATED11$488,1652023
Janssen Research & Development, LLC5$448,5142023
Edwards Lifesciences Corporation76$255,7602023
Alexion Pharmaceuticals, Inc.3$230,1202023
BioFire Diagnostics, LLC7$192,8262023
Gen-Probe, Inc.1$175,1952023
Merck Sharp & Dohme LLC5$150,1132023
PFIZER INC.35$147,6532023
Ultragenyx Pharmaceutical Inc.20$115,4172023
Eli Lilly and Company14$112,7282023
Amgen Inc.5$101,1332023
ALBIREO PHARMA, INC.24$76,9602023
Novo Nordisk AS606$46,1932023
Travere Therapeutics, Inc.27$43,8772023
Gilead Sciences, Inc.15$38,4392023
Immedica Pharma US, Inc.4$36,3542023
Rhythm Pharmaceuticals, Inc.6$29,2302023
AstraZeneca UK Limited1$25,8502023
Phadia US Inc.1$25,0002023
QIAGEN, LLC1$23,3592023
Bayer Healthcare Pharmaceuticals Inc.3$20,2002023
AKEBIA THERAPEUTICS INC4$19,0522023
JAZZ PHARMACEUTICALS INC.3$18,0002023
Apellis Pharmaceuticals, Inc.2$16,7252023
Hyperfine Operations, Inc.1$16,4362023
National Marrow Donor Program6$16,0552023
Bio-Rad Laboratories, Inc.1$13,0102023
ABBVIE INC.7$12,3642023
HEMA Biologics, LLC3$12,0002023
AstraZeneca Pharmaceuticals LP1$12,0002023
Stryker Corporation8$11,9612023
Organon Llc2$11,4752023
Abbott Laboratories1$9,1292023
QOL Medical, LLC4$8,9752023
Boehringer Ingelheim Pharmaceuticals, Inc.1$8,5652023
IBSA Institut Biochimique SA3$7,2032023
Astellas Pharma Global Development5$7,0052023
New York Blood Center, Inc.1$6,4802023
GLOBAL BLOOD THERAPEUTICS, INC.3$5,1232023
E.R. Squibb & Sons, L.L.C.1$5,0002023
Incyte Corporation2$5,0002023
Takeda Pharmaceuticals U.S.A., Inc.2$4,0002023
Becton, Dickinson and Company1$3,5902023
Kedrion Biopharma, Inc.1$3,0002023
KLS-Martin L.P.2$2,5742023
Mirum Pharmaceuticals, Inc.1$2,0312023
Streck LLC5$1,6502023
Linvatec Corporation1$1,2732023
AMAG Pharmaceuticals, Inc.1$1,0002023
GlaxoSmithKline, LLC.1$6292023

By nature of payment

NatureRecordsAmount
Research payment920$2,522,694
Compensation for services other than consulting, including serving as faculty or as a speaker at a v10$481,759
Long term medical supply or device loan9$13,235
Consulting Fee6$4,650
Debt forgiveness2$2,574
Space rental or facility fees (teaching hospital only)2$1,200

Records

DateCompanyAmountNatureFormProductStudyYear
2023-12-31Stryker Corporation$11,200Long term medical supply or device loanIn-kind items and servicesUNIVERSAL NEURO 2, UNIVERSAL NEURO III Device, NEURO SPINE ENT2023
2023-12-31Linvatec Corporation$1,273Long term medical supply or device loanIn-kind items and servicesHANDSTAND Device, ORTHOPEDIC SURGERY2023
2023-12-31Merck Sharp & Dohme LLC$281Research paymentIn-kind items and servicesJANUVIA Drug, ENDOCRINOLOGYA Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac2023
2023-12-31Stryker Corporation$212Long term medical supply or device loanIn-kind items and servicesSONOPET IQ Device, NEURO SPINE ENT2023
2023-12-31Stryker Corporation$100Long term medical supply or device loanIn-kind items and servicesREMB Device, SURGICAL2023
2023-12-31Stryker Corporation$100Long term medical supply or device loanIn-kind items and servicesREMB Device, SURGICAL2023
2023-12-31Stryker Corporation$100Long term medical supply or device loanIn-kind items and servicesREMB Device, SURGICAL2023
2023-12-31Stryker Corporation$100Long term medical supply or device loanIn-kind items and servicesREMB Device, SURGICAL2023
2023-12-31Merck Sharp & Dohme LLC$78Research paymentIn-kind items and servicesNOXAFIL Drug, INFECTIOUS DISEASEA Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous IV and Powder for Oral Suspension Formulations2023
2023-12-31Stryker Corporation$72Long term medical supply or device loanIn-kind items and servicesREMB Device, SURGICAL2023
2023-12-31Stryker Corporation$72Long term medical supply or device loanIn-kind items and servicesREMB Device, SURGICAL2023
2023-12-31Merck Sharp & Dohme LLC$38Research paymentCash or cash equivalentJANUVIA Drug, ENDOCRINOLOGYA Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac2023
2023-12-28Streck LLC$330Consulting FeeCash or cash equivalent2023
2023-12-27ALBIREO PHARMA, INC.$1,751Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro2023
2023-12-27PFIZER INC.$526Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-12-22Abbott Laboratories$9,129Research paymentCash or cash equivalentFreeStyle Libre 2 Device, Diabetes CareFreeStyle Libre 2 Flash Glucose Monitoring System Intervention Phase Study2023
2023-12-21ALBIREO PHARMA, INC.$5,582Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr2023
2023-12-21ALBIREO PHARMA, INC.$5,000Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr2023
2023-12-19AstraZeneca UK Limited$25,850Research paymentCash or cash equivalentFASENRA Biological, RespiratoryMulticentre,Randomised,Double blind,Parallel Group,Placebo controlled,Time to first Asthma Exacerbation Phase tree Effic2023
2023-12-19HEMA Biologics, LLC$3,000Research paymentCash or cash equivalentSevenFact Biological, HematologyATHN 162023
2023-12-19HEMA Biologics, LLC$3,000Research paymentCash or cash equivalentSevenFact Biological, HematologyATHN 162023
2023-12-19Ultragenyx Pharmaceutical Inc.$2,342Research paymentCash or cash equivalentUX143-CL3012023
2023-12-18Novo Nordisk AS$1,080Research paymentCash or cash equivalentNN7415-48072023
2023-12-18Travere Therapeutics, Inc.$90Research paymentCash or cash equivalentA Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre2023
2023-12-14Edwards Lifesciences Corporation$17,508Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112023
2023-12-14Edwards Lifesciences Corporation$9,832Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2023
2023-12-14Edwards Lifesciences Corporation$284Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2023
2023-12-13E.R. Squibb & Sons, L.L.C.$5,000Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase IIA Nivo in HL Pediatric (nivo+bv) - A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults 2023
2023-12-12Ultragenyx Pharmaceutical Inc.$1,624Research paymentCash or cash equivalentUX143-CL3012023
2023-12-11Immedica Pharma US, Inc.$3,100Research paymentCash or cash equivalentA Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp2023
2023-12-07Edwards Lifesciences Corporation$3,200Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2023
2023-12-06Merck Sharp & Dohme LLC$89,562Research paymentCash or cash equivalentPNEUMOVAX 23 Biological, VACCINEImmunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients2023
2023-12-05Bayer Healthcare Pharmaceuticals Inc.$3,600Research paymentCash or cash equivalentKerendia Drug, Cardio-renalFinerenone paediatric CKD trial2023
2023-11-30Ultragenyx Pharmaceutical Inc.$1,955Research paymentCash or cash equivalentUX143-CL3012023
2023-11-28Ultragenyx Pharmaceutical Inc.$12,250Research paymentCash or cash equivalentUX143-CL3012023
2023-11-27Rhythm Pharmaceuticals, Inc.$2,500Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0352023
2023-11-27Rhythm Pharmaceuticals, Inc.$1,500Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0352023
2023-11-27Rhythm Pharmaceuticals, Inc.$750Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0352023
2023-11-27Novo Nordisk AS$720Research paymentCash or cash equivalentNN7415-48072023
2023-11-27Rhythm Pharmaceuticals, Inc.$500Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0352023
2023-11-27Rhythm Pharmaceuticals, Inc.$350Research paymentCash or cash equivalentImcivree Drug, Genetic DiseaseRM-493-0352023
2023-11-22Edwards Lifesciences Corporation$5,967Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112023
2023-11-22Edwards Lifesciences Corporation$5,200Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2023
2023-11-22Travere Therapeutics, Inc.$2,306Research paymentCash or cash equivalentA Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre2023
2023-11-22Novo Nordisk AS$630Research paymentCash or cash equivalentSogroya Biological, Growth HormoneNN8640-42632023
2023-11-22Edwards Lifesciences Corporation$568Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Early Feasibility (2016-04)2023
2023-11-22Edwards Lifesciences Corporation$450Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112023
2023-11-22Edwards Lifesciences Corporation$408Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112023
2023-11-22Edwards Lifesciences Corporation$354Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2023
2023-11-21Gilead Sciences, Inc.$2,924Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2023
2023-11-21Ultragenyx Pharmaceutical Inc.$1,064Research paymentCash or cash equivalentUX143-CL3012023
2023-11-21Ultragenyx Pharmaceutical Inc.$358Research paymentCash or cash equivalentUX143-CL3012023
2023-11-21Travere Therapeutics, Inc.$70Research paymentCash or cash equivalent021IGAN170012023
2023-11-20Travere Therapeutics, Inc.$3,390Research paymentCash or cash equivalentA Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre2023
2023-11-20Travere Therapeutics, Inc.$875Research paymentCash or cash equivalentA Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre2023
2023-11-15Gen-Probe, Inc.$175,195Research paymentCash or cash equivalentPANTHER FUSION Device, DiagnosticsComparison of nasal swab and nasopharyngeal swab for respiratory testing using Hologic Panther Fusion assay2023
2023-11-15ABBVIE INC.$1,500Research paymentCash or cash equivalentDALVANCE Drug, ANTI-INFECTIVEDalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to b2023
2023-11-10QOL Medical, LLC$500Research paymentCash or cash equivalentSucraid Drug, THERAPY FOR CSIDQOL Pediatric Sucraid2023
2023-11-09Astellas Pharma Global Development$315Research paymentCash or cash equivalentCresemba Drug, Infectious DiseasesA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2023
2023-11-08PFIZER INC.$117Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-11-06Edwards Lifesciences Corporation$13,724Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112023
2023-11-06Ultragenyx Pharmaceutical Inc.$12,536Research paymentCash or cash equivalentUX143-CL3012023
2023-11-06Edwards Lifesciences Corporation$2,000Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2023
2023-11-06Edwards Lifesciences Corporation$408Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesALTERRA Post-Approval Study 2021-112023
2023-11-06Edwards Lifesciences Corporation$354Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2023
2023-11-02Astellas Pharma Global Development$2,130Research paymentCash or cash equivalentCresemba Drug, Infectious DiseasesA Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco2023
2023-11-02ALBIREO PHARMA, INC.$1,400Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr2023
2023-11-02ALBIREO PHARMA, INC.$1,300Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr2023
2023-11-02ALBIREO PHARMA, INC.$525Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro2023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$11Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023
2023-10-31Novo Nordisk AS$3Research paymentIn-kind items and servicesNN7415-48072023

The latest 200 records of 949.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

In Missouri; placed by its state only.

MeasureState
Missouri
Population B010036,191,814
Population, 2020 census P16,154,913
Median age B0100239.0
Under 18 B0100122.3%
65 and over B0100117.9%
Households B110012,508,227
Foreign born B050024.5%
Median household income B19013$70,702
Median family income B19113$91,360
Per capita income B19301$39,695
Poverty rate B1700112.6%
Unemployment rate B230254.0%
Civilian labor force B230253,120,639
Mean commute (minutes) B0801323.5
Bachelor's degree or higher B1500332.4%
Housing units B250012,825,287
Owner-occupied B2500368.1%
Renters B2500331.9%
Median home value B25077$230,300
Median gross rent B25064$1,033
White, not Hispanic B0300276.3%
Black B0300210.9%
Hispanic or Latino B030025.2%
Asian B030022.1%
American Indian and Alaska Native B030020.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Missouri.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.